Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.

Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression. The company went public …

Dec 30, 2025 · Tempus AI has strong Data and Services bookings, but multi-year revenue conversion tempers near-term growth. TEM plans a measured MRD ramp as reimbursement …

Dec 18, 2025 · Tempus is a public company based in Chicago (United States), founded in 2015 by Eric Lefkofsky. It operates as an AI-based precision medicine solutions for oncology. …

TEMPUS® is a technology company that has built the world's largest library of clinical and molecular data and an operating system to make that information accessible and useful for …

17 hours ago · In recent days, Tempus AI has attracted strong institutional attention as Ark Invest bought shares through its ARK Genomic Revolution and ARK Innovation ETFs, while options …

2 days ago · On Monday, Jan. 5, 2026, Cathie Wood-led ark purchased Tempus AI and Kodiak AI shares while selling Roku and Shopify stock

Feb 25, 2025 · Tempus operates at the intersection of artificial intelligence and healthcare, employing machine learning to process complex biological datasets. Its platform provides …

5 days ago · Complete Tempus AI Inc. stock information by Barron's. View real-time TEM stock price and news, along with industry-best analysis.

For clinicians associated with advanced research initiatives, Tempus provides next-generation genomic profiling, biological organoid modeling, image/pattern AI recognition, and a range of …